Innocoll to Report Third Quarter 2016 Financial Results and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Innocoll to Report Third Quarter 2016 Financial Results and Host Webcast and Conference Call on November 22, 2016

ATHLONE, Ireland, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq: INNL ), a global, specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical need, today announced that it will report third quarter financial results before the open of U.S. financial markets on November 22, 2016. Innocoll management will host a webcast and conference call at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

Interested parties may access the live webcast and call through the Investors section of the company website at www.innocoll.com or directly through the registration link . A recording will be archived on the company website for 90 days.

The live call may be accessed by dialing 877-407-9039 for domestic callers and 201-689-8470 for international callers. A telephone replay of the call will be available until 11:59 p.m. ET on November 29, 2016 by dialing 877-870-5176 for domestic callers or 858-384-5517 for international callers and entering the conference code: 48285346.

About Innocoll Holdings PLC

Innocoll is a global, commercial-stage, specialty pharmaceutical company that is dedicated to engineering better medicines to help patients get better. Our proprietary, biocompatible, and biodegradable collagen products are precision-engineered for targeted use. Applied locally to surgery sites, they are designed to provide a range of benefits. The company's late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XARACOLL® for the treatment of postoperative pain and COLLAGUARD (INL-003), a barrier for the prevention of post-surgical adhesions.

Our currently approved products include: COLLAGUARD® (ex-US), COLLATAMP® G, SEPTOCOLL® E, REGENEPRO®, COLLACARE®, COLLEXA®, and ZORPREVA®, some of which are sold globally through strategic partnerships, including those with Takeda, EUSA Pharma, Biomet 3i and Biomet.  All of our native collagen products — from extraction/purification of type-1 collagen through final delivery form — are manufactured at our certified, integrated plant in Saal, Germany.

For more information, please visit  www.innocoll.com . CollaRx ® , Collatamp ® , COLLAGUARD ® , Collieva ® , CollaCare ® , Collexa ® , COGENZIA ® LidoColl ® , LiquiColl ® , and XARACOLL® are registered trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are trademarks of the company.

Contact: Pepe Carmona Chief Financial Officer (215) 983-3362 pcarmona@innocoll.com Jeannie Sorenson, M.D. Vice President, Investor Relations (314) 458-7355 jsorenson@innocoll.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 52

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 28

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 36

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 46

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 63

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 38

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 40

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading

Top 5 Most Recently Viewed Articles

Peter Schiff's Insights: The Golden Edge Over Stocks

Updated Category News Views 256

Gold's Decades-Long Dominance Over Equities Peter Schiff, a well-known economist, emphasizes the impressive performance of gold over equities for nearly 60 years. He notes that even though the Dow Jones has seen a near 50-fold increase since 1966, gold has considerably outperformed equities, achieving a remarkable 120-fold increase in value during the same timeframe. In...

Continue Reading
Exploring Hidden Wealth: Jim Rickards' Insights on U.S. Resources

Updated Category News Views 392

Revealing America’s Abundant Untapped Resources As discussions sharpen over financing significant economic initiatives tied to President Trump's administration, intriguing insights have resurfaced. A presentation from economic strategist Jim Rickards has drawn attention for proposing that the U.S. may possess essential resources that could be leveraged to support these...

Continue Reading
Middle West Spirits Welcomes Old Elk Distillery to Its Family

Updated Category News Views 344

Middle West Spirits Expands National Footprint Middle West Spirits, a prominent name in the distilling world, has recently taken significant steps forward by acquiring Old Elk Distillery, celebrated for its exceptional whiskeys. This union not only adds to Middle West Spirits' impressive portfolio but also signifies a promising collaboration that aims to take the whiskey...

Continue Reading
Citi Downgrades Kering: Insights on Brand Challenges

Updated Category News Views 57

Citi Downgrades Kering: Insights on Brand Challenges Recently, Citi took action regarding Kering (EPA:PRTP) by adjusting its stock recommendation from Buy to Neutral. Along with changing the stock rating, a revised price target was also set at €264.00, lowered from an earlier target of €350.00. This decision reflects the increasing difficulties the luxury goods...

Continue Reading
Apple's Steps forward to Rescind iPhone Sales Ban in Indonesia

Updated Category News Views 155

Apple Inc's Negotiations to Lift iPhone Sales Ban Apple Inc (NASDAQ: AAPL) is making notable strides in its efforts to resolve the recent ban on iPhone sales imposed by the Indonesian government. Reports indicate that the tech giant is on the verge of finalizing an agreement that could lead to the lifting of this restriction, as confirmed by a government minister familiar...

Continue Reading